Fosun Pharma Sustainability Profile
Fosun Pharma, officially known as Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is a leading global healthcare company headquartered in China. Established in 1994, the firm has expanded its operations across major regions, including Asia, Europe, and North America, positioning itself as a key player in the pharmaceutical and healthcare industry. Fosun Pharma focuses on research and development, manufacturing, and distribution of innovative medicines, vaccines, and medical devices. Its core products, which include a diverse range of therapeutic solutions, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, including strategic partnerships and acquisitions that enhance its market presence. With a strong emphasis on innovation and a robust pipeline, Fosun Pharma continues to solidify its position as a prominent force in the global healthcare landscape.
DitchCarbon Score
How does Fosun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fosun Pharma's score of 53 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fosun Pharma's reported carbon emissions
In 2024, Fosun Pharma reported total carbon emissions of approximately 929,435,000 kg CO2e, comprising 184,016,000 kg CO2e from Scope 1, 653,644,000 kg CO2e from Scope 2, and 91,775,000 kg CO2e from Scope 3. This marked a slight decrease from 2023, where total emissions were about 960,864,000 kg CO2e, with Scope 1 emissions at 210,819,000 kg CO2e, Scope 2 at 677,874,000 kg CO2e, and Scope 3 at 72,171,000 kg CO2e. Fosun Pharma has set ambitious reduction targets, aiming for a 10% reduction in comprehensive energy consumption intensity by 2025 compared to 2020 levels, targeting 2.287 GJ/RMB 10,000 revenue. Additionally, they aim for a 15% reduction in carbon emission intensity for Scope 2 emissions by 2025, targeting 0.23 tons/RMB 10,000 revenue. The company is also committed to achieving net zero emissions by 2050, as proposed by the International Energy Agency. This long-term goal reflects their dedication to addressing climate change and reducing their overall carbon footprint. Fosun Pharma's emissions data is inherited from its parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., ensuring a comprehensive understanding of their environmental impact and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 288,447,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 457,732,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Fosun Pharma's Industry?
How Carbon Intensive is Fosun Pharma's Location?
Fosun Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fosun Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
